Light Mode
$3.58 ↑ +0.00 (+0.00%) Trading Up from the previous close of $3.58, $0.07 below the day’s high of $3.66
-4.06 (-53.14%) / 6M
Momentum, market sentiment, and recent alerts
RLMD reads very good: price sits above one of the two key moving averages, the 12-month move is +58.4%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Relmada Therapeutics, Inc. engages in the development of clinical-stage drugs. The firm's pipeline includes NDV-01 and Sepranolone. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.